1	World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030 [EB/OL]. (2022-07-18) [2024-11-25]. https://www.who.int/publications/i/item/9789240053779 本文引用 [2]

2	CUI FQ, BLACH S, MANZENGO MINGIEDI C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C[J]. Lancet Gastroenterol Hepatol, 2023, 8(4): 332-342. DOI: 10.1016/S2468-1253(22)00386-7 . 本文引用 [1]

3	GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Gastroenterol Hepatol, 2022, 7(9): 796-829. DOI: 10.1016/S2468-1253(22)00124-8 . 本文引用 [3]

4	ZHENG H, WANG Y, WANG FZ, et al. New progress in HBV control and the cascade of health care for people living with HBV in China: Evidence from the fourth national serological survey, 2020[J]. Lancet Reg Health West Pac, 2024, 51: 101193. DOI: 10.1016/j.lanwpc.2024.101193 . 本文引用 [2]

5	WANG FZ, ZHENG H, SUN XJ, et al. Achievements and prospects for hepatitis B prevention and control in China[J]. Chin J Vaccines Immun, 2019, 25(5): 487-492. 王富珍, 郑徽, 孙校金, 等. 中国控制乙型病毒性肝炎的成就与展望[J]. 中国疫苗和免疫, 2019, 25(5): 487-492. 本文引用 [2]

6	COLLABORATORS PO. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6 . 本文引用 [1]

7	LIU J, WANG XY, WANG Q, et al. Hepatitis B virus infection among 90 million pregnant women in 2 853 Chinese counties, 2015-2020: A national observational study[J]. Lancet Reg Health West Pac, 2021, 16: 100267. DOI: 10.1016/j.lanwpc.2021.100267 . 本文引用 [1]

8	ZHAO K, ZHANG YH. History of the Development of Biological Products in China (1910—1990)[M]. Beijing: Beijing Institute of Biological Products, 2003. 赵铠, 章以浩. 中国生物制品发展史略: 1910—1990[M]. 北京: 北京生物制品研究所, 2003. 本文引用 [2]

9	ZHAO H, ZHOU XY, ZHOU YH. Hepatitis B vaccine development and implementation[J]. Hum Vaccin Immunother, 2020, 16(7): 1533-1544. DOI: 10.1080/21645515.2020.1732166 . 本文引用 [1]

10	LIANG XF, BI SL, YANG WZ, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China[J]. J Infect Dis, 2009, 200(1): 39-47. DOI: 10.1086/599332 . 本文引用 [1]

11

WANG AL, SONG L. Safeguarding the starting point of life to protect maternal and child health: A review and prospect of the prevention of mother-to-child transmission of HIV, syphilis and hepatitis B in China in the past 20 years[J]. Chin J AIDS STD, 2021, 27(7): 677-679. DOI: 10.13419/j.cnki.aids.2021.07.01 . 王爱玲, 宋莉. 守护生命起点保障母婴健康: 中国预防艾滋病梅毒和乙肝母婴传播工作20年回顾与展望[J]. 中国艾滋病性病, 2021, 27(7): 677-679. DOI: 10.13419/j.cnki.aids.2021.07.01 . 本文引用 [1]

12	WANG AL, QIAO YP, WANG LH, et al. Integrated prevention of mother-to-child transmission for human immunodeficiency virus, syphilis and hepatitis B virus in China[J]. Bull World Health Organ, 2015, 93(1): 52-56. DOI: 10.2471/BLT.14.139626 . 本文引用 [1]

13

National Health Commission. Immunization schedules and instructions for vaccines of the national immunization program(2021 version) [EB/OL]. (2021-03-12)[2024-11-25]. http://www.nhc.gov.cn/jkj/s3581/202103/590a8c7915054aa682a8d2ae8199e222.shtml 国家卫生健康委. 国家免疫规划疫苗儿童免疫程序及说明(2021年版) [EB/OL]. (2021-03-12)[2024-11-25]. http://www.nhc.gov.cn/jkj/s3581/202103/590a8c7915054aa682a8d2ae8199e222.shtml 本文引用 [1]

14	World Health Organization. Hepatitis B vaccines: WHO position paper-July 2017[J]. Wkly Epidemiol Rec, 2017, 92(27): 369-392. DOI: 10.1016/j.vaccine.2017.07.046 . 本文引用 [2]

15	World Health Organization. Global health sector strategy on viral hepatitis 2016-2021 [EB/OL]. (2016-06-01) [2024-11-25]. http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/ 本文引用 [1]

16	Ministry of Health. National plan for hepatitis B prevention and treatment, 2006-2010[J]. Chin Pract J Rural Dr, 2006, 13(8): 1-4. DOI: 10.3969/j.issn.1672-7185.2006.08.001 . 中华人民共和国卫生部. 2006年～2010年全国乙型病毒性肝炎防治规划[J]. 中国实用乡村医生杂志, 2006, 13(8): 1-4. DOI: 10.3969/j.issn.1672-7185.2006.08.001 . 本文引用 [1]

17

National Health and Family Planning Commisson, National Development and Reform Commisson, Ministry of Education, et al. Action plan for the prevention and treatment of viral hepatitis in China (2017-2020)[EB/OL]. (2017-11-10)[2024-11-25]. http://www.nhc.gov.cn/jkj/s3581/201711/aea94a8c1d9d4110a13e2b4d8418c173.shtml 国家卫生计生委, 国家发展改革委, 教育部, 等. 中国病毒性肝炎防治规划(2017-2020年) [EB/OL]. (2017-11-10)[2024-11-25]. http://www.nhc.gov.cn/jkj/s3581/201711/aea94a8c1d9d4110a13e2b4d8418c173.shtml 本文引用 [2]

18

National Health Commission. Action Plan for Eliminating Mother-to-child Transmission of AlDS, Syphilis and Hepatitis B(2022-2025)[EB/OL]. (2022-12-30)[2024-11-25]. http://www.nhc.gov.cn/fys/s3581/202212/afe6bc9626be45a0b25bee93f01fef10.shtml 国家卫生健康委员会. 消除艾滋病、梅毒和乙肝母婴传播行动计划(2022-2025年)[EB/OL]. (2022-12-30)[2024-11-25]. http://www.nhc.gov.cn/fys/s3581/202212/afe6bc9626be45a0b25bee93f01fef10.shtml 本文引用 [1]

19	World Health Organization. Immunization coverage [EB/OL]. (2024-07-15)[2024-12-18]. https://www.who.int/news-room/fact-sheets/detail/immunization-coverage 本文引用 [1]

20

Obstetrics Subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association, Chinese Society of Perinatal Medicine, Chinese Medical Association. 2020 clinical guidelines on prevention of mother-to-child transmission of hepatitis B virus[J]. J Clin Hepatol, 2020, 36(7): 1474-1481. DOI: 10.3760/cma.j.cn112141-20200213-00101 . 中华医学会妇产科学分会产科学组, 中华医学会围产医学分会. 乙型肝炎病毒母婴传播预防临床指南(2020)[J]. 临床肝胆病杂志, 2020, 36(7): 1474-1481. DOI: 10.3760/cma.j.cn112141-20200213-00101 . 本文引用 [1]

21	YIN XR, WANG W, CHEN H, et al. Real-world implementation of a multilevel interventions program to prevent mother-to-child transmission of HBV in China[J]. Nat Med, 2024, 30(2): 455-462. DOI: 10.1038/s41591-023-02782-x . 本文引用 [1]

22

YE JK, CAO L, YU WZ, et al. Reported routine immunization coverage with National Immunization Program vaccines in China, 2020-2021[J]. Chin J Vaccines Immun, 2022, 28(5): 576-580. DOI: 10.19914/j.CJVI.2022110 . 叶家楷, 曹雷, 余文周, 等. 中国2020—2021年国家免疫规划疫苗常规免疫报告接种率[J]. 中国疫苗和免疫, 2022, 28(5): 576-580. DOI: 10.19914/j.CJVI.2022110 . 本文引用 [1]

23	LIU J, LIANG WN, JING WZ, et al. Countdown to 2030: Eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3): 230-238. DOI: 10.2471/BLT.18.219469 . 本文引用 [1]

24

MIAO N, WANG FZ, ZHENG H, et al. Hepatitis B vaccine coverage and factors influencing coverage among children 1-14 years of age in China in 2020[J]. Chin J Vaccines Immun, 2022, 28(6): 679-683. DOI: 10.19914/j.CJVI.2022125 . 缪宁, 王富珍, 郑徽, 等. 2020年中国1-14岁儿童乙型肝炎疫苗接种率和影响因素[J]. 中国疫苗和免疫, 2022, 28(6): 679-683. DOI: 10.19914/j.CJVI.2022125 . 本文引用 [1]

25	HUANG LF, HUANG AD, ZHANG X, et al. Immunization status and factors influencing hepatitis B vaccination of preterm infants in three provinces of China, 2019 to 2021[J]. BMC Infect Dis, 2024, 24(1): 951. DOI: 10.1186/s12879-024-09846-4 . 本文引用 [1]

26

ZHENG H, WANG FZ, CHEN YS, et al. The hepatitis B prevalence and the vaccination statutes of the 1-14 years-old children in eastern, central and western areas of China[J]. Chin J Vaccines Immun, 2012, 18(1): 19-25. DOI: 10.19914/j.cjvi.2012.01.005 . 郑徽, 王富珍, 陈园生, 等. 中国东中西部地区1～14岁儿童乙型病毒性肝炎流行现状及乙型肝炎疫苗接种情况[J]. 中国疫苗和免疫, 2012, 18(1): 19-25. DOI: 10.19914/j.cjvi.2012.01.005 . 本文引用 [1]

27

HU YH, DUNZHU DJ, LI Q/X), et al. Epidemiological survey of hepatitis B and analysis of hepatitis B vaccine coverage rate among children aged 1-14 years in Lhasa in 2006, 2014 and 2020[J]. Chin J Prev Med, 2023, 57(3): 406-410. DOI: 10.3760/cma.j.cn112150-20221105-01072 . 胡永红, 顿珠多吉, 李茜, 等. 2006和2014及2020年拉萨市1～14岁儿童乙肝流行病学调查及乙肝疫苗接种率分析[J]. 中华预防医学杂志, 2023, 57(3): 406-410. DOI: 10.3760/cma.j.cn112150-20221105-01072 . 本文引用 [1]

28	World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection [EB/OL]. (2024-03-29)[2024-12-18]. https://www.who.int/publications/i/item/9789240090903 本文引用 [1]

29	SANDUL AL, RAPPOSELLI K, NYENDAK M, et al. Updated recommendation for universal hepatitis B vaccination in adults aged 19-59 years - United States, 2024[J]. MMWR Morb Mortal Wkly Rep, 2024, 73(48): 1106. DOI: 10.15585/mmwr.mm7348a3 . 本文引用 [1]

30	WU ZK, BAO HD, YAO J, et al. Suitable hepatitis B vaccine for adult immunization in China: A systematic review and meta-analysis[J]. Hum Vaccin Immunother, 2019, 15(1): 220-227. DOI: 10.1080/21645515.2018.1509172 . 本文引用 [1]

31

Working Committee of Promoting the Elimination of Viral Hepatitis of Chinese Preventive Medicine Association, Society of Prevention and Control of Infectious Diseases of Chinese Preventive Medicine Association. Expert recommendations on hepatitis B vaccination in adults[J]. J Clin Hepatol, 2024, 40(8): 1551-1556. DOI: 10.12449/JCH240808 . 中华预防医学会促进消除病毒性肝炎工作委员会, 中华预防医学会感染性疾病防控分会. 成人乙型肝炎疫苗接种专家建议[J]. 临床肝胆病杂志, 2024, 40(8): 1551-1556. DOI: 10.12449/JCH240808 . 本文引用 [1]

32

ZHENG H, WANG FZ, ZHANG GM, et al. The epidemiological characteristics of HBV susceptibility in 1-29 years old young people in China in 2006 and 2014: Based on the national sero-survey data analysis[J]. Chin J Prev Med, 2017, 51(7): 581-586. DOI: 10.3760/ema.j.issn.0253-9624.2017.07.002 . 郑徽, 王富珍, 张国民, 等. 2006和2014年中国1-29岁乙型肝炎病毒易感人群的流行病学特征分析[J]. 中华预防医学杂志, 2017, 51(7): 581-586. DOI: 10.3760/ema.j.issn.0253-9624.2017.07.002 . 本文引用 [1]

33

MA TL, PAN LL, GAO Z, et al. Influencing factors of coverage rate of hepatitis B vaccine among adults in Hebei Province[J]. Chin Prev Med, 2019, 20(4): 303-307. DOI: 10.16506/j.1009-6639.2019.04.014 . 马田莉, 潘璐璐, 高招, 等. 河北省成年人乙肝疫苗接种率影响因素研究[J]. 中国预防医学杂志, 2019, 20(4): 303-307. DOI: 10.16506/j.1009-6639.2019.04.014 . 本文引用 [1]

34

XU Y, WU QQ, XU SY, et al. Analysis on hepatitis B vaccination and its influencing factors among adults in Zhejiang Province[J]. Chin J Health Educ, 2020, 36(3): 259-261, 284. DOI: 10.16168/j.cnki.issn.1002-9982.2020.03.015 . 许燕, 吴青青, 徐水洋, 等. 浙江省部分地区成人乙肝疫苗接种情况及影响因素分析[J]. 中国健康教育, 2020, 36(3): 259-261, 284. DOI: 10.16168/j.cnki.issn.1002-9982.2020.03.015 . 本文引用 [1]

35	YUAN QL, WANG FZ, ZHENG H, et al. Hepatitis B vaccination coverage among health care workers in China[J]. PLoS One, 2019, 14(5): e0216598. DOI: 10.1371/journal.pone.0216598 . 本文引用 [1]

36	AN J, JIN N, XIE JR, et al. Vaccination coverage of hepatitis B and associated factors among health care workers in Gansu province[J]. Hum Vaccin Immunother, 2024, 20(1): 2383509. DOI: 10.1080/21645515.2024.2383509 . 本文引用 [1]

37	HOU XB, LI N, ZHANG HL, et al. Hepatitis B virus infection and vaccination among people who use drugs in Xi’an, China[J]. Vaccine, 2024, 42(24): 126259. DOI: 10.1016/j.vaccine.2024.126259 . 本文引用 [1]

38	WANG C, WANG YX, HUANG XJ, et al. Prevalence and factors associated with hepatitis B immunization and infection among men who have sex with men in Beijing, China[J]. PLoS One, 2012, 7(10): e48219. DOI: 10.1371/journal.pone.0048219 . 本文引用 [1]

39	DOLHAIN J, JANSSENS W, DINDORE V, et al. Infant vaccine co-administration: Review of 18 years of experience with GSK’s hexavalent vaccine co-administered with routine childhood vaccines[J]. Expert Rev Vaccines, 2020, 19(5): 419-443. DOI: 10.1080/14760584.2020.1758560 . 本文引用 [2]

40	World Health Organization. Vaccination schedule for Hepatitis B [EB/OL]. [2024-11-25]. https://immunizationdata.who.int/pages/schedule-by-disease/hepatitisb.html?ISO_3_CODE=&TARGETPOP_GENERAL= 本文引用 [2]

41	BAYLISS J, NISSEN M, PRAKASH D, et al. Control of vaccine preventable diseases in Australian infants: Reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine[J]. Hum Vaccin Immunother, 2021, 17(1): 176-190. DOI: 10.1080/21645515.2020.1764826 . 本文引用 [1]

42

KLEIN NP, ABU-ELYAZEED R, CHEUVART B, et al. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: A randomized trial in the United States[J]. Hum Vaccin Immunother, 2019, 15(4): 809-821. DOI: 10.1080/21645515.2018.1549449 .

43	SCHWARZ TF, BEHRE U, ADELT T, et al. Long-term antibody persistence against hepatitis B in adolescents 14-15-years of age vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy[J]. Hum Vaccin Immunother, 2019, 15(1): 235-241. DOI: 10.1080/21645515.2018.1509658 . 本文引用 [1]

44	LANG S, LOVING S, MCCARTHY ND, et al. Two centuries of immunisation in the UK (part II)[J]. Arch Dis Child, 2020, 105(3): 216-222. DOI: 10.1136/archdischild-2019-317707 . 本文引用 [1]

45	KALIES H, GROTE V, SIEDLER A, et al. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany’s experience after 5 years of licensure[J]. Vaccine, 2008, 26(20): 2545-2552. DOI: 10.1016/j.vaccine.2008.03.001 . 本文引用 [1]

46	ZHENG H, WANG FZ, ZHANG GM, et al. An economic analysis of adult hepatitis B vaccination in China[J]. Vaccine, 2015, 33(48): 6831-6839. DOI: 10.1016/j.vaccine.2015.09.011 . 本文引用 [1]